Guardant Health, Inc. - Common Stock (NQ:GH)

177.80 +3.05 (+1.75%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence

March 21, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Earnings Perspective: Return On Capital Employed ↗

March 16, 2023

Via Benzinga

Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

March 10, 2023

From Guardant Health, Inc.

Via Business Wire

2 Stocks That Could Rebound and Rise 30% or More in 2023 ↗

March 10, 2023

They're down, but they aren't yet out.

Via The Motley Fool

Looking Into Guardant Health's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Analyst Expectations for Guardant Health's Future ↗

February 27, 2023

Via Benzinga

Earnings Outlook For Guardant Health ↗

February 22, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market ↗

March 06, 2023

Investing now is an admittedly risky bet, but the payoff could be massive.

Via The Motley Fool

Musa Tariq Joins Guardant Health Board of Directors

February 27, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

February 23, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming March Investor Conferences

February 17, 2023

From Guardant Health, Inc.

Via Business Wire

25 AI Stocks to Buy Right Now ↗

February 16, 2023

Looking to benefit from the AI boom started by ChatGPT? Here are the best AI stocks to buy for the emerging market frenzy.

Via InvestorPlace

Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer

February 15, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer

February 08, 2023

From Guardant Health, Inc.

Via Business Wire

Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development ↗

February 04, 2023

Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...

Via Talk Markets

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

February 02, 2023

From Guardant Health Inc.

Via Business Wire

Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina

February 02, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 01, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery

January 31, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer

January 30, 2023

From Guardant Health, Inc.

Via Business Wire

Down 40% in 2022, Can Exact Sciences Recover in 2023? ↗

January 23, 2023

Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous.

Via The Motley Fool

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

January 19, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers

January 17, 2023

From Guardant Health, Inc.

Via Business Wire

Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla ↗

January 11, 2023

Shares of Exact Sciences, Inc. (NASDAQ: EXAS) have been on a tear, having gained over 27% in two sessions this week.

Via Benzinga

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results

January 09, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 28, 2022

From Guardant Health, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

December 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

December 21, 2022

From Guardant Health, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.